pemigatinib + trastuzumab

**Pemigatinib + trastuzumab** is a combination therapy of two targeted antineoplastic agents. **Pemigatinib** is a selective, potent, oral small molecule inhibitor of fibroblast growth factor receptor (FGGR) 1, 2, and 3, primarily developed for cancers with FGFR alterations. **Trastuzumab** is a recombinant humanized monoclonal antibody targeting the HER2 (human epidermal growth factor receptor 2), approved for HER2-positive cancers such as breast and gastric cancer. The combination is under investigation as a potential treatment for patients with advanced solid tumors, particularly those with HER2-positive gastric or gastro-esophageal junction cancers that have become resistant to trastuzumab-containing regimens. The rationale is based on evidence that FGFR signaling mediates resistance to HER2-targeted therapy; thus, co-inhibition of FGFR and HER2 may overcome resistance and offer clinical benefit in these cancers[1][2][3][7].